News | Artificial Intelligence | May 14, 2021

Algorithms must be tested and continually monitored to assess impact of bias

Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address

Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address inherent biases in healthcare algorithms and their deployment. Image courtesy of Regenstrief Institute


May 14, 2021 — Artificial intelligence (AI)-driven healthcare has the potential to transform medical decision-making and treatment, but these algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients.

In a JAMA Network Open Invited Commentary, Regenstrief Institute President and Chief Executive Officer and Indiana University School of Medicine Associate Dean for Informatics and Health Services Research Peter Embí, M.D., M.S., strongly stated the importance of algorithmovigilance to address inherent biases in healthcare algorithms and their deployment. Algorithmovigilance, a term coined by Dr. Embí, can be defined as the scientific methods and activities relating to the evaluation, monitoring, understanding, and prevention of adverse effects of algorithms in healthcare.

"We wouldn't think of treating patients with a new pharmaceutical or device without first ensuring its efficacy and safety," said Embí. "In the same way, we must recognize that algorithms have the potential for both great benefit and harm and, therefore, require study. Also, compared with drugs or devices, algorithms often have additional complexities and variations, such as how they are deployed, who interacts with them, and the clinical workflows where interactions with algorithms take place."

The commentary was in response to a study from IBM scientists evaluating different approaches to debiasing healthcare algorithms developed to predict postpartum depression. Embí stated the study suggests that debiasing methods can help address underlying disparities represented in the data used to develop and deploy the AI approaches. He also said the study demonstrates that the evaluation and monitoring of these algorithms for effectiveness and equity is necessary and even ethically required.

"Algorithmic performance changes as it is deployed with different data, different settings and different human-computer interactions. These factors could turn a beneficial tool into one that causes unintended harm, so these algorithms must continually be evaluated to eliminate the inherent and systemic inequities that exist in our healthcare system," Embí continued. "Therefore, it's imperative that we continue to develop tools and capabilities to enable systematic surveillance and vigilance in the development and use of algorithms in healthcare."

For more information: www.regenstrief.org


Related Content

News | RSNA

December 5, 2022 — With AI becoming an integral part of clinical radiology workflows, the data used to develop AI ...

Time December 05, 2022
arrow
News | Artificial Intelligence

December 2, 2022 — emtelligent, a leader in the development of clinical-grade natural language processing (NLP) software ...

Time December 02, 2022
arrow
News | Artificial Intelligence

December 1, 2022 — VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has announced the availability of ...

Time December 01, 2022
arrow
News | Artificial Intelligence

December 1, 2022 — Annalise.ai and Nuance announced that the global medical imaging AI company has joined the Nuance ...

Time December 01, 2022
arrow
News | Artificial Intelligence

December 1, 2022 — At the 2022 Radiological Society of North America (RSNA) Annual Meeting, Peter R. Eby, MD, of ...

Time December 01, 2022
arrow
Feature | RSNA | Christine Book

November 30, 2022 — On the fourth day of RSNA 2022, inside Chicago’s McCormick Place, an estimated 260 separate events ...

Time December 01, 2022
arrow
News | Artificial Intelligence

November 30, 2022 — Ziosoft, a pioneer in 3D/4D AI medical visualization, is introducing its newest software for its ...

Time November 30, 2022
arrow
News | Artificial Intelligence

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10 ...

Time November 29, 2022
arrow
News | PACS

November 28, 2022 — At this week’s Radiological Society of North America (RSNA) annual meeting (November 27 – December 1 ...

Time November 28, 2022
arrow
News | Mammography

November 28, 2022 — The Radiological Society of North America (RSNA) has announced the launch of the RSNA Screening ...

Time November 28, 2022
arrow
Subscribe Now